Literature DB >> 31444673

Variations in external reference pricing implementation: does it matter for public policy?

Jennifer Gill1, Anna-Maria Fontrier2, Dionysis Kyriopoulos2, Panos Kanavos2.   

Abstract

BACKGROUND: External reference pricing (ERP) seeks to rationalize prices and contain costs using foreign prices as a reference for the determination of domestic prices and is often used as the starting point for the facilitation of negotiations between health authorities and pharmaceutical manufacturers.
METHODS: A systematic literature review was used to identify characteristics of ERP implementation across 29 countries. Primary data collection, in the form of surveys directed at key stakeholders, was also used to supplement data in instances where information received from the systematic literature review was outdated or minimal. Findings from the systematic literature review and primary evidence from key stakeholders were bench-marked against 14 best practice principles inherent to an optimal ERP system.
RESULTS: Significant heterogeneity in ERP implementation across countries was identified. Country basket size, pricing calculation, and frequency of price revisions varied between countries. Belgium, France, and South Africa were more likely to adhere to the best practice principles, whilst Bulgaria, Hungary, and Romania had the most instances of non-adherence.
CONCLUSION: The observed heterogeneity has policy implications for governments including globally declining pharmaceutical prices, launch delays in lower income countries, reduced incentive for continued R&D, and reduced access to medicines. Overcoming this issue to ensure that ERP is beneficial to all stakeholders will require a focus on developing sustainable, transparent, simple, and stable systems using a set of key guidelines that should maximize the benefits of the pricing policy.

Entities:  

Keywords:  Expert consultation; External reference pricing; Pharmaceutical policy; Regulation of pharmaceuticals; Systematic review

Mesh:

Year:  2019        PMID: 31444673     DOI: 10.1007/s10198-019-01100-y

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  21 in total

1.  Russian Federation. Health system review.

Authors:  Larisa Popovich; Elena Potapchik; Sergey Shishkin; Erica Richardson; Alexandra Vacroux; Benoit Mathivet
Journal:  Health Syst Transit       Date:  2011

2.  Greece: Health system review.

Authors:  Charalambos Economou
Journal:  Health Syst Transit       Date:  2010

3.  Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

4.  Drug Launch Timing and International Reference Pricing.

Authors:  Nicolas Houy; Izabela Jelovac
Journal:  Health Econ       Date:  2014-07-07       Impact factor: 3.046

Review 5.  Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.

Authors:  Tuan Anh Nguyen; Rosemary Knight; Elizabeth Ellen Roughead; Geoffrey Brooks; Andrea Mant
Journal:  Health Policy Plan       Date:  2014-01-13       Impact factor: 3.344

6.  Turkey. Health system review.

Authors:  Mehtap Tatar; Salih Mollahaliloğlu; Bayram Sahin; Sabahattin Aydin; Anna Maresso; Cristina Hernández-Quevedo
Journal:  Health Syst Transit       Date:  2011

Review 7.  Italy: health system review.

Authors:  Francesca Ferre; Antonio Giulio de Belvis; Luca Valerio; Silvia Longhi; Agnese Lazzari; Giovanni Fattore; Walter Ricciardi; Anna Maresso
Journal:  Health Syst Transit       Date:  2014

8.  Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?

Authors:  Helle Håkonsen; Anne Marie Horn; Else-Lydia Toverud
Journal:  Health Policy       Date:  2008-11-29       Impact factor: 2.980

Review 9.  Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.

Authors:  Sabine Vogler; Claudia Habl; Martina Bogut; Luka Voncina
Journal:  Croat Med J       Date:  2011-04-15       Impact factor: 1.351

10.  Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.

Authors: 
Journal:  J Pharm Policy Pract       Date:  2015-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.